Larimar Therapeutics (LRMR) Change in Account Payables (2013 - 2025)

Larimar Therapeutics (LRMR) has reported Change in Account Payables for 13 consecutive years, with -$5.8 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Change in Account Payables fell 890.38% year-over-year to -$5.8 million; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (up 144.7% YoY), and the FY2025 full-year result was $2.8 million, up 144.7% from the prior year.
• Change in Account Payables eased to -$5.8 million in Q4 2025 per LRMR's latest filing, from $6.9 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $6.9 million in Q3 2025 and bottomed at -$5.8 million in Q4 2025.
• Historically, Change in Account Payables has averaged $129100.0 across 5 years, with a median of $435500.0 in 2022.
• The sharpest annual moves came in 2022 and 2025: Change in Account Payables soared 1045.36% in 2022, then tumbled 890.38% in 2025.
• Over 5 years, Change in Account Payables stood at -$97000.0 in 2021, then jumped by 1045.36% to $917000.0 in 2022, then plunged by 42.53% to $527000.0 in 2023, then jumped by 40.04% to $738000.0 in 2024, then sank by 890.38% to -$5.8 million in 2025.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$5.8 million, $6.9 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.